Mesoblast trading update: strong revenue growth and pipeline momentum.
Mesoblast Limited (ASX: MSB) delivered a robust trading update at its AGM, highlighting accelerating commercial demand for Ryoncil. For the quarter ending December 31, 2025, the Company expects gross revenue above US$30 million, reflecting an increase of more than 37% over the prior quarter. This strong uplift is driven by expanding adoption of Ryoncil, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft versus host disease.
The Company continues progressing its diversified cell therapy pipeline across adult SR-aGvHD, biologic-resistant inflammatory bowel disease, heart failure and chronic low-back pain. With a global portfolio of more than 1,000 patents extending to at least 2044 and established commercial partnerships in Japan, Europe and China, Mesoblast is reinforcing its position as a leader in scalable, off-the-shelf cellular medicines.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Mesoblast trading update: strong revenue growth and pipeline momentum.
Mesoblast Limited (ASX: MSB) delivered a robust trading update at its AGM, highlighting accelerating commercial demand for Ryoncil. For the quarter ending December 31, 2025, the Company expects gross revenue above US$30 million, reflecting an increase of more than 37% over the prior quarter. This strong uplift is driven by expanding adoption of Ryoncil, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft versus host disease.
The Company continues progressing its diversified cell therapy pipeline across adult SR-aGvHD, biologic-resistant inflammatory bowel disease, heart failure and chronic low-back pain. With a global portfolio of more than 1,000 patents extending to at least 2044 and established commercial partnerships in Japan, Europe and China, Mesoblast is reinforcing its position as a leader in scalable, off-the-shelf cellular medicines.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au